BioAegis Therapeutics Inc., a privately held biotechnology company exploiting plasma gelsolin’s (pGSN) role in immune function, announced that it has expanded its clinical advisory board to include McGowan Institute for Regenerative Medicine affiliated faculty member John Kellum, MD. Dr. Kellum is a Professor in the Departments of Critical Care Medicine (primary), Medicine, Bioengineering, and Clinical and Translational Science at the University of Pittsburgh. He is the Director of the Center for Critical Care Nephrology and the Vice-Chair for Research, both appointments in the Department of Critical Care Medicine, and Associate Director for Acute Illness in the Institute for Personalized Medicine at Pitt. Dr. Kellum also serves as an Intensivist in the Cardiothoracic ICU at UPMC.
Dr. Kellum’s research interests span various aspects of Critical Care Medicine, but center in critical care nephrology (including acid-base, and renal replacement therapy), sepsis and multi-organ failure (including blood purification), and clinical epidemiology. His research has received continuous funding from the National Institutes of Health since 2001, and he has active funding from multiple different NIH Institutes. Dr. Kellum has authored more than 300 publications and has also edited several major textbooks including Critical Care Nephrology and Stewart’s Textbook of Acid-Base.
Read more…